Full-Time

Associate Director

Feasibility

Posted on 5/21/2025

Takeda

Takeda

10,001+ employees

Global biopharmaceutical firm; R&D-driven NMEs

Compensation Overview

$153.6k - $241.3k/yr

Massachusetts, USA

Remote

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis
Requirements
  • BS degree or international equivalent in a life science required, advanced degree preferred.
  • 8 or more years of experience in Clinical Operations, Data Analytics, global feasibility, and trial optimization with evidence of increasing responsibility within a pharmaceutical company, CRO or relevant industry vendor required.
  • 7 or more years of direct responsibility in leading strategic feasibility assessments of global clinical research studies at a sponsor or CRO including at least 2 years of country and site selection responsibilities.
  • Experience with leading edge trial optimization vendors, tools, and methods.
  • Proficiency with software models and database structures.
  • Expertise in principles of data-driven country/site identification and selection, feasibility, and study start-up planning.
  • Direct experience in the pharmaceutical industry or related field required.
  • Ability to demonstrate, interpret, explain, represent, and drive unbiased data insights into clinical trials operational planning.
  • Ability to develop deep insights, uncover unmet needs, drive innovation, inspire, develop, collaborate and lead within a global matrixed team.
  • Ability to explain data in order to facilitate decision making processes to be data driven.
Responsibilities
  • Manage feasibility activities at a program and/or asset level with minimal oversight by the Therapeutic-aligned Director of Feasibility.
  • Conduct data-driven feasibility assessments for Phase I – IV clinical studies, including protocol design optimization, country/site identification, enrollment strategy and modeling across therapeutic areas.
  • Utilize internal and external competitive intelligence platforms/tools to develop benchmark assumptions that enable data-driven program/study timeline projections, country and site identification, and robust enrollment forecasts.
  • Collaborate with operational leads and other cross-functional stakeholders to increase understanding of metrics and forecasts particularly with respect to enrollment timeline analytics.
  • Contribute in efforts to implement innovative processes, methodologies, data and technologies that ensures continuous improvement and innovation of valued Feasibility services.
  • Participate in or lead global initiatives representing Clinical Site Startup & Engagement (CSSE) in support of Takeda R&D objectives.
  • Contribute to Clinical Development Plans, providing directional timeline estimates and high-level enrollment projections driven by available historical trial/industry performance data.
  • Accountable for the development of feasibility analyses to maximize efficiency, effectiveness, and acceleration in Takeda’s operational execution of its clinical research studies.
  • May be responsible for the oversight and direction of Feasibility staff contributing to asset(s) for which the AD is responsible.
  • Ensures consistent standards are applied to the feasibility process across the portfolio and directs continuous improvement activities while developing and implementing TA-aligned strategies/approaches.
  • Develops TA/Indication expertise and act as feasibility subject matter expert in order to contribute to protocol design discussions.
  • Lead country and site selection process to ensure data-driven decisions are made through: Collection, analysis, and presentation of internal and external data (e.g., local treatment standard of care, available treatment options approved/reimbursed, local incidence/prevalence of disease, access to targeted patient population, drug landscape, historical/current clinical trial landscape) to define an optimal geographic country footprint and proposed sites for participation in a clinical study.
  • In partnership with internal stakeholders synthesize, interpret, and integrate data and information to provide clear feasibility recommendations to strengthen data-driven decision making, analyze trends, identify root causes, and provide actionable recommendations across study teams and programs to accelerate study execution.
  • Regularly reviews ongoing study performance in relation to projected study timelines and, in collaboration with the Takeda study team and CRO, is responsible for re-forecasting patient enrollment models to adjust for new influence factors (e.g., change in drug landscape, protocol amendment, increased screen failure rate).
  • Identifies study performance risk and assist study team in mitigation planning. Exhibit the ability to perform root cause analysis and determine mitigation steps to removing critical path roadblocks related to study execution and patient enrollment.
Desired Qualifications
  • Strong analytical competencies. Exposure to and understanding of clinical data sets as it relates to clinical trial planning, forecasting and execution.
  • Customer focus, analytical mindset with attention to detail. experience with information systems and clinical trial intelligence and supporting data.
  • Demonstrated experience managing and collaborating in a matrix work environment. Ability to direct activities and influence outcomes without direct authority. Ability to work independently and handle multiple projects.
  • Demonstrated business acumen especially in relation to interacting with higher-level staff in an efficient, effective, and respectful manner.
  • Extremely proficient with MS Office applications.

Takeda is a global biopharmaceutical company focused on discovering and delivering medicines and vaccines to improve patient health. It relies on extensive research and development to create new molecular entities (NMEs) and bring them to market, aiming for up to 15 product launches through FY2024 from a pipeline of 11 NMEs. Revenue comes mainly from selling pharmaceutical products, supported by about 41,000 third-party suppliers worldwide. The company differentiates itself through a deep history (over 240 years), a broad portfolio of global brands, and a patient-centric approach that places patients’ needs at the center of its operations while pursuing environmental sustainability. Takeda’s goal is to advance health globally by turning scientific innovations into accessible therapies, maintaining long-term growth through steady product innovation and responsible operations.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Zasocitinib Phase 3 data shows 50% patients achieve clear skin, NDA submission in FY2026.
  • Rusfertide gains exclusive global rights post-Protagonist opt-out, PDUFA Q3 2026.
  • New Strategy & Portfolio unit integrates BD, launched January 29, 2026.

What critics are saying

  • Lays off 247 Cambridge workers starting July 2026, eroding R&D talent.
  • Terminates Denali partnership April 3, 2026, loses $150M dementia investment.
  • Incoming CEO Julie Kim sparks Japan-US board clashes, accelerates neuroscience divestitures.

What makes Takeda unique

  • Takeda focuses on oncology, rare diseases, neuroscience, gastroenterology, and plasma-derived therapies.
  • Founded in 1781, Takeda holds 240-year Japanese heritage in biopharmaceutical innovation.
  • Acquired zasocitinib from Nimbus for $4 billion in 2022 to target psoriasis market.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
BioSpace
Apr 6th, 2026
Takeda breaks up with Denali, dumps dementia drug.

Takeda breaks up with Denali, dumps dementia drug. April 6, 2026 | Takeda and Denali Therapeutics first partnered in early 2018 to advance drugs for neurodegenerative diseases. One asset, for Alzheimer's disease, was previously discontinued after an FDA hold and disappointing early data. More than eight years after linking up, Takeda and Denali Therapeutics are going their separate ways, with the Japanese pharma handing all rights to a dementia program back to Denali. Takeda's decision to terminate its partnership with Denali "was driven by strategic considerations," the California biotech said in an SEC document dated April 3, and "is not related to efficacy or safety data." The Japanese pharma informed Denali of its decision that same day, according to the securities filing. The companies inked their partnership in January 2018, with Takeda fronting $150 million and promising unspecified milestone payments. Takeda and Denali had also previously been working on the TREM2 agonist DNL919 for Alzheimer's disease - but this molecule's development path has been bumpy. In January 2022, the FDA slapped a clinical hold on the asset, though the partners at the time did not disclose why. The hold was eventually lifted, but Takeda and Denali in August 2023 nevertheless discontinued DNL919's development, pointing to Phase 1 findings suggesting the drug had only a "narrow therapeutic window." In 2021, Takeda also exercised its option to co-develop and co-commercialize DNL593, a protein replacement therapy that can cross the blood-brain barrier, for frontotemporal dementia. That asset has since been returned to Denali, the biotech said on April 3. "We are looking forward to advancing DNL593 independently," CEO Ryan Watts said in a press statement that day, adding that the company "remain[s] confident" in the scientific rationale behind DNL593. DNL593 works by replacing the progranulin protein, which in frontotemporal dementia is deficient, leading to lysosomal defects that, in turn, result in the accumulation of toxins across different tissues. The asset is currently in a Phase 1/2 study, enrollment for which has completed with 40 recruited participants, according to Denali's April 3 release. There have been no reported safety signals to date, the biotech noted. Phase 1/2 data for DNL593 are expected before the end of this year, Watts said. Takeda's pullback comes just days after Denali delivered a much-needed win for the rare disease space with the FDA approval of its Hunter syndrome therapy Avlayah. Like DNL593, Avlayah works by replacing a deficient player, this time targeting the IDS enzyme, which under healthy conditions clears toxic byproducts from several organs, including the brain. Avlayah is the first Hunter syndrome therapy in nearly 20 years and is the first FDA-approved treatment to exploit the transferrin pathway to cross the blood-brain barrier. Avlayah is the first Hunter syndrome therapy approved to address the condition's neurologic complications, according to Tracy Beth Høeg, acting director of the Center for Drug Evaluation and Research. March 26, 2026

The Boston Globe
Mar 31st, 2026
Pharma giant Takeda to lay off nearly 250 local workers in latest job cutting.

Pharma giant Takeda to lay off nearly 250 local workers in latest job cutting. By Marin Wolf Globe Staff, Updated March 30, 2026, 10:00 a.m. Takeda Pharmaceuticals will lay off nearly 250 workers in Cambridge, the state's largest biopharma employer announced through a state filing. The layoffs will begin in July, although some will take place later in the year or in 2027. All affected Massachusetts employees work at the company's 500 Kendall St. location, according to the filing posted Friday. The workforce reduction is part of a cost-saving plan approved by Takeda's board of directors on March 25 that is expected to result in annual savings of about $1.25 billion by 2028, according to a company statement. Another 387 workers in other states may also be laid off as part of the plan.

Yahoo Finance
Mar 30th, 2026
Takeda Pharmaceuticals to cut 247 jobs in Cambridge as part of $1.2B cost-cutting plan

Takeda Pharmaceuticals, Massachusetts' largest biopharmaceutical employer, will lay off 247 employees at its Cambridge headquarters as part of a broader corporate restructuring. The redundancies begin on 1 July and could extend into 2027. The Japanese company announced cost-cutting measures expected to save approximately $1.2 billion by 2028. An additional 387 employees will be laid off in other US states. Affected workers are receiving transition assistance, including help identifying internal opportunities. Takeda currently has around 700 open positions, including 300 in Massachusetts, with internal candidates given priority. The company employs more than 5,700 people in Massachusetts and occupies approximately 2.8 million square feet of real estate. This follows 137 layoffs announced in October and over 800 Massachusetts redundancies in 2024.

BioSpace
Mar 30th, 2026
Takeda restructuring could push more than 600 US staffers out of jobs.

Takeda restructuring could push more than 600 US staffers out of jobs. March 30, 2026 | Takeda's layoffs include cutting 247 people in Massachusetts. The workforce reduction is meant to help offset investments in areas including a product launch for oral drug candidate zasocitinib, for which the pharma today announced positive Phase 3 data. The workforce impact of Takeda's recently announced reorganization has become clearer. The Japan-based pharma estimates the restructuring will affect around 634 U.S. employees, according to a Worker Adjustment and Retraining Notification (WARN) Act notice. Takeda began notifying employees on March 25, the same day it announced a business transformation, which includes streamlining corporate functions. However, the company noted in the WARN notice that the total number affected could change as staff pursue and accept redeployment opportunities across its global network. Takeda's cuts include 247 employees in Cambridge, Massachusetts, effective July 1, 2026, through Dec. 31, 2027. To understand where other layoffs will take place, BioSpace has requested a copy of a document mentioned in the WARN notice that lists the number of individuals affected by state. In last week's announcement, Takeda noted that the restructuring, which includes "strategically prioritizing resources," is expected to save more than 200 billion yen - about $1.25 billion - by fiscal year 2028. The company explained that the savings will offset investments needed to prepare for multiple launches, including oveporexton, usfertide and zasocitinib; progress the late-stage pipeline; and support strategic technology investments. Takeda announced today promising data for zasocitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate to severe plaque psoriasis. In the Phase 3 Latitude PsO 3001 and 3002 studies, more than half of patients treated with the drug candidate achieved clear or almost clear skin at week 16, a key measure of treatment success, according to the pharma. Zasocitinib also demonstrated statistically significant improvements in complete skin clearance. Takeda expects to submit a new drug application for zasocitinib in fiscal year 2026. The pharma acquired zasocitinib from Nimbus Therapeutics for $4 billion at the end of 2022 to challenge Bristol Myers Squibb's kinase inhibitor Sotyktu. Takeda in December 2025 reported positive results from the Phase 3 LATITUDE studies, noting that when compared with placebo and Amgen's Otezla, about 30% of treated patients achieved completely clear skin, or a score of 100 on the Psoriasis Area and Severity Index (PASI). The company's latest layoffs join a series of cuts from the past two years. Takeda let go of nearly 1,500 employees in the U.S. and Austria in 2024 and early 2025 and 137 in October 2025. In January, news broke that 243 people would be laid off across its U.S. operations.

Healthcare Asia Magazine
Mar 30th, 2026
Takeda Healthcare Philippines, Inc. wins at Healthcare Asia Pharma Awards 2026.

Takeda Healthcare Philippines, Inc. wins at Healthcare Asia Pharma Awards 2026. The access programme and advocacy initiative closed affordability gaps for Filipino patients. Takeda Healthcare Philippines, Inc. won Most Differentiated Service of the Year - Philippines and Patient Advocacy Program of the Year - Philippines in the Healthcare Asia Pharma Awards 2026 for its access model that supports patients from disease awareness to therapy completion. In a healthcare system where many patients face delayed diagnosis, long referral pathways, and high out-of-pocket costs, the company built a differentiated and sustainable service anchored on its Patient Assistance Program (PAP). The programme follows a clear principle: therapy completion should not depend on a patient's ability to pay. PAP uses an affordability-based assessment to evaluate each eligible patient's circumstances and set a contribution aligned to what the patient can reasonably afford for the full course of treatment. This structured, patient-level approach supports equity whilst maintaining business viability. It is not a standard discount model but a tailored access scheme designed for Filipino patients and adaptable to changing circumstances. The operating model involves independent third parties assessing financial support needs and informing programme design. Patients share in the cost of treatment, whilst Takeda Healthcare Philippines, Inc. collaborates with local authorities and partners to help cover the remaining cost. The company embeds access within hospital pathways through collaborations with organisations such as the Tzu Chi Foundation, private institutions, and major hospitals, helping reduce out-of-pocket expenses and improve coordination across the patient journey. Join Healthcare Asia Magazine community To date, more than 1,300 Filipino patients have received support through Takeda's access programme, including patients living with Hodgkin lymphoma, inflammatory bowel disease, and other rare conditions. By enabling therapy completion, the programme helps patients return to work or school and resume caregiving roles, reducing the broader social and economic burden of untreated disease. Beyond affordability, the company addresses inequity in geographically isolated and disadvantaged areas by working with partners to strengthen patient navigation and connections to appropriate providers and specialists. Through Access to Medicines Summits and partnership frameworks, it also supports patients in accessing available private and government funding. A key milestone in its advocacy efforts is the inclusion of life-saving treatment for rare diseases such as haemophilia in the Philippine National Formulary, enabling free access to essential medicines in government hospitals following partnerships and a positive health technology assessment. The Healthcare Asia Pharma Awards shines a spotlight on the outstanding companies redefining pharmaceutical excellence in Asia. It lauds those who redefine the pharmaceutical landscape through innovative, unique initiatives that have significantly enhanced their businesses. The Healthcare Asia Pharma Awards is presented by Healthcare Asia Magazine. To view the full list of winners, click here. If you want to join the 2027 awards programme and be recognised for your organisation's innovative and unique initiatives that enhanced your business and remarkable contributions to the pharmaceutical industry, please contact Julie Anne Nuñez-Difuntorum at [email protected].

INACTIVE